MBX MBX Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1776111 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-80.3%
TTM EPS YoY-139.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-33.7%
ROA-32.2%
ROIC (approx.)-53.3%
Asset turnover—
Leverage & solvency
Liabilities / assets5.5%
Debt / equity0.00x
Current ratio19.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $79.16M | $57.41M | $28.53M |
| SG&A expense | $18.90M | $10.78M | $6.78M |
| Operating income | -$98.06M | -$68.19M | -$35.31M |
| Pretax income | -$87.00M | -$61.90M | — |
| Income tax | $0 | $0 | $0 |
| Net income | -$86.97M | -$61.92M | -$32.56M |
| EBITDA | -$97.81M | -$67.95M | -$35.15M |
| EPS (basic) | -2.38 | -5.82 | -31.96 |
| EPS (diluted) | -2.38 | -5.82 | -31.96 |
| Weighted avg. shares (diluted) | 36.51M | 10.64M | 1.02M |
| Balance sheet | |||
| Cash & equivalents | $75.29M | $49.35M | $30.52M |
| Short-term investments | $298.42M | $212.80M | $50.15M |
| Current assets | $381.54M | $267.29M | $83.47M |
| PP&E, net | $2.73M | $1.08M | $439,000 |
| Total assets | $385.14M | $268.54M | $84.18M |
| Current liabilities | $15.49M | $11.05M | $3.93M |
| Total liabilities | $15.92M | $11.09M | $4.29M |
| Shareholders' equity | $369.22M | $257.44M | -$72.47M |
| Shares outstanding | 44.93M | 33.42M | 1.26M |
| Cash flow statement | |||
| Operating cash flow | -$79.95M | -$54.68M | -$31.98M |
| Capital expenditure | $1.93M | $874,000 | $129,000 |
| Free cash flow | -$81.88M | -$55.55M | -$32.11M |
| Investing cash flow | -$83.70M | -$160.59M | -$30.93M |
| Financing cash flow | $189.59M | $234.10M | $69.22M |
| Depreciation & amortization | $248,000 | $244,000 | $157,000 |
| Stock-based compensation | $8.68M | $5.22M | $2.04M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.